SGLT2 inhibitors and the cardiorenal continuum: a paradigm shift in the treatment of patients with T2D
Keywords: 
Type 2 diabetes
SGLT2 inhibitors
Cardiorenal
Cardiovascular disease
Kidney disease
Heart failure
Morbidity
Mortality
Chronic kidney disease
Cardiorenal continuum
Issue Date: 
2022
ISSN: 
1869-6953
Note: 
This article is licensed under a Creative Commons Attribution-NonCommer- cial 4.0 International License
Citation: 
Escalada-San Martín, F. (Francisco Javier). "SGLT2 inhibitors and the cardiorenal continuum: a paradigm shift in the treatment of patients with T2D". Diabetes therapy. 13 (Supl. 1), 2022, 1 - 3
Abstract
Type 2 diabetes mellitus (T2D) represents a sig- nificant public health problem, with a dramat- ically increasing prevalence. T2D is considered a progressive disease that develops macro- and microvascular complications such as cardiovas- cular disease (CVD), heart failure (HF), and chronic kidney disease (CKD), which are closely interconnected and constitute the main causes of morbidity and mortality in these patients. Over time, finding new pharmacological approaches to protect against these cardiorenal events (the ‘‘cardiorenal continuum’’) has become the fundamental objective of research aimed at these patients.

Files in This Item:
Thumbnail
File
pdf.pdf
Description
Size
163.47 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.